SLC5A2 and familial dilated cardiomyopathy: With the advent of SGLT2 inhibitors, intervention on a number of pathways, both related to diabetes and more likely common pro-inflammatory and pro-fibrotic pathways, has already impacted significantly on improving outcomes for patients with heart failure and DCM.